Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.239 USD | +3.46% | -48.02% | -39.08% |
06-28 | ADRs Advance; Connect Biopharma Holdings Climbs 19% | DJ |
06-28 | EARNINGS AND TRADING: Thruvision loss widens but Polarean loss narrows | AN |
Sales 2024 * | 2.5M 3.44M | Sales 2025 * | 6.98M 9.58M | Capitalization | 21.46M 29.49M |
---|---|---|---|---|---|
Net income 2024 * | -32M -43.97M | Net income 2025 * | -24M -32.98M | EV / Sales 2024 * | 8.58 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.08 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.53% |
Latest transcript on Renalytix Plc
1 day | +3.46% | ||
1 week | -48.02% | ||
Current month | +2.86% | ||
1 month | -45.22% | ||
3 months | -71.21% | ||
6 months | -44.09% | ||
Current year | -39.08% |
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
Howard Doran
PSD | President | 63 | 23-08-31 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-07-01 | 0.2376 | +2.86% | 143 917 |
24-06-28 | 0.231 | -10.85% | 863,873 |
24-06-27 | 0.2591 | +3.52% | 599,083 |
24-06-26 | 0.2503 | -28.97% | 1,430,886 |
24-06-25 | 0.3524 | -22.91% | 692,978 |
Delayed Quote Nasdaq, July 01, 2024 at 11:59 am
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-56.00% | 2.22B | |
+23.17% | 1.82B | |
-18.13% | 1.43B | |
+20.34% | 1.23B | |
+0.52% | 784M | |
-31.31% | 741M | |
-37.37% | 723M | |
-29.12% | 602M | |
+16.75% | 564M |
- Stock Market
- Equities
- RENX Stock
- RNLX Stock